The widespread infectious diseases coupled with the growth in consumption of inhibitor drugs among the population promotes the growth of the Beta-lactam and Beta-lactamase inhibitor market.

The Beta-lactam and Beta-lactamase Inhibitor Market is expected to grow at a CAGR of 1.9% from 2020-2030, according to a new research report by Next Move Strategy Consulting.

Beta-lactam inhibitors fall under a drug class of antibiotic agents that help fight against bacterial infections and protozoa infections. Beta-lactam inhibitors either kill the bacteria directly or restrict it from multiplying. Beta-lactamase Inhibitors fall under a class of drugs that restrict the activity of beta-lactamase enzymes and limit the degradation of beta-lactam. Some examples of beta-lactam inhibitors are penicillin, cephalosporin etc.

According to the report, the rise in consumption of such beta-lactam and beta-lactamase inhibitors combined with the widespread presence of infectious diseases are among the major factors that promote the beta-lactam and beta-lactamase inhibitor market growth.

The beta-lactam and beta-lactamase inhibitor market report is segmented by drug class, disease, route of administration, and geography. Based on drug class, the beta-lactam and beta-lactamase inhibitor market share is segmented into penicillin, cephalosporin, carbapenem, monobactam, and combination. The combination is sub-segmented into penicillin/beta-lactamase inhibitor, cephalosporin/beta-lactamase inhibitor, and carbapenem/beta-lactamase inhibitor. Based on disease, the beta-lactam and beta-lactamase inhibitor market is categorized into urinary tract infection, respiratory infection, complicated urinary tract infection, complicated intra-abdominal infection, and nosocomial pneumonia. Nosocomial pneumonia is sub-segmented into hospital-acquired pneumonia, ventilator-associated pneumonia, and other nosocomial pneumonia. Based on the route of administration, the beta-lactam and beta-lactamase inhibitor market is segmented into oral, intravenous, and other routes. In terms of Geography, the market is categorized into North America, Europe, Asia Pacific, and the rest of the world.

At present, the North American region holds the highest market size & share in the beta-lactam and beta-lactamase inhibitor market because of developed health infrastructure and technology. Due to the growth in consumption of beta-lactam and beta-lactamase inhibitors in the Asia Pacific region, this region is predicted to show rapid market growth.

According to the report, some of the key players in the market are Allergan Plc., Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Merck & Co. Inc., Pfizer Inc., Novartis International AG (Sandoz), Teva Pharmaceutical Industries Ltd., Sanofi and more.

Browse key industry insight from the report, Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2020–2030

Key Insights from the Beta-lactam and Beta-lactamase Inhibitors Market Report:

• Current emerging trends and opportunities are extensively analysed in the Beta-Lactam and Beta-lactamase Inhibitor market report.
• The forecast of the Beta-Lactam and Beta-lactamase Inhibitor market comes along with additional information associated with opportunities, restrains and key drivers in the market.

Get a free sample of the Beta-Lactam and Beta-lactamase Inhibitor market report

About Next Move Strategy Consulting

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, browse reports